Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Antiretroviral Therapy for Acute HIV Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03877536
Recruitment Status : Withdrawn (Feeder cohort study closed.)
First Posted : March 15, 2019
Last Update Posted : April 26, 2019
Sponsor:
Collaborator:
Gilead Sciences
Information provided by (Responsible Party):
Henry M. Jackson Foundation for the Advancement of Military Medicine

Tracking Information
First Submitted Date  ICMJE September 26, 2018
First Posted Date  ICMJE March 15, 2019
Last Update Posted Date April 26, 2019
Estimated Study Start Date  ICMJE March 17, 2019
Estimated Primary Completion Date September 14, 2023   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 14, 2019)
  • Plasma viral load [ Time Frame: Measured at 48 weeks after enrollment ]
    The number of study participants with plasma viral load <50 copies/mL
  • Plasma viral load [ Time Frame: Measured at 96 weeks after enrollment ]
    The number of study participants with plasma viral load <50 copies/mL
  • Drug-related AEs and SAEs [ Time Frame: Measured through week 96 ]
    Occurrence of drug-related adverse events and serious adverse events at any time from enrollment up to 96 weeks after enrollment early HIV infection.
  • Treatment Discontinuation for AEs up to 96 weeks [ Time Frame: Measured through week 96 ]
    Tolerability of treatment as measured by treatment discontinuation for AEs up to 96 weeks
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 14, 2019)
  • CD4+ T cell count change [ Time Frame: Measured over 48 weeks ]
    CD4+ T cell count change over first 48 weeks as compared to baseline.following the initiation of Genvoya®
  • Frequency of HIV-related illnesses [ Time Frame: Measured through week 96 ]
    Frequency of HIV-related illnesses (including acute retroviral syndrome)
  • Duration of HIV-related illnesses [ Time Frame: Measured through week 96 ]
    Duration of HIV-related illnesses (including acute retroviral syndrome)
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: March 14, 2019)
  • Changes in HIV-specific immune responses over time [ Time Frame: Measured through week 96 ]
    Description of changes in HIV-specific immune responses over time as characterized by intracellular cytokine staining (ICS)
  • Host humoral (IgG) responses [ Time Frame: Measured through week 96 ]
    Characterization of evolution in host humoral (IgG) responses to HIV envelope over time including development of neutralizing antibody responses
  • Markers of Immune Activation [ Time Frame: Measured through week 96 ]
    Description of markers of immune activation (soluble and cellular markers) by ICS.
  • HIV reservoir size [ Time Frame: Measured through week 96 ]
    Evaluation of the HIV reservoir size by measurement of 1) single copy HIV RNA quantification in samples with HIV RNA <50 copies/mL and 2) total HIV DNA and integrated HIV DNA in peripheral blood
  • Neuropsychological battery performance [ Time Frame: Measured through week 96 ]
    Evaluation of neuropsychological battery performance at week 48 and 96; and to later compare to RV 217 data from pre-infection and baseline early or acute HIV infection timepoints.
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Antiretroviral Therapy for Acute HIV Infection
Official Title  ICMJE Antiretroviral Therapy for Acute HIV Infection
Brief Summary This study will evaluate the virologic effect, safety and tolerability of Genvoya® in adults during early acute HIV infection.
Detailed Description This is a prospective, open-label study to describe the effects of early antiretroviral (ART) therapy on 1) viral load, 2) safety and tolerability of Genvoya®, 3) clinical outcomes and secondarily on HIV-specific immune responses. This study is a sub-study of RV 217 that will recruit participants with incident HIV diagnoses from the parent RV 217 cohort. Potential RV 392 volunteers will be recruited from the RV 217 ECHO cohort if they have been diagnosed with incident HIV Infection. Screening procedures for HIV in RV 217 are designed to identify participants during acute HIV infection (AHI) or early HIV infection. Participants will initiate Genvoya®, a once a day antiretroviral pill within 1 week of enrollment. RV 392 follow-up visits will largely overlap with RV 217 visits for the study duration of 96 weeks, but additional visits will occur early after initiation of Genvoya®. RV 392 participants will remain co-enrolled in RV 217 (i.e., RV 217 visits also continue); blood collection will be coordinated by the RV 392 team by prioritizing safety labs and then research labs within the allotted blood volumes while still meeting scientific objectives for both RV 217 and RV 392. Blood tests that are required for both protocols will only be collected once and will not be duplicated across the two protocols.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description:
prospective, open-label study
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE HIV Infections
Intervention  ICMJE Drug: Genvoya 150Mg-150Mg-200Mg-10Mg Tablet
Participants will receive 1 tablet per day throughout study duration (96 weeks).
Study Arms  ICMJE Experimental: Genvoya 150Mg-150Mg-200Mg-10Mg Tablet
Genvoya® (Elvitegravir, corbiscistat, Emtricitabine and Tenofovir Alafenamide): once a day antiretroviral pill starting within 1 week of enrollment.
Intervention: Drug: Genvoya 150Mg-150Mg-200Mg-10Mg Tablet
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Withdrawn
Actual Enrollment  ICMJE
 (submitted: April 24, 2019)
0
Original Estimated Enrollment  ICMJE
 (submitted: March 14, 2019)
100
Estimated Study Completion Date  ICMJE September 14, 2025
Estimated Primary Completion Date September 14, 2023   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. First identified as an incident HIV infection within one year of estimated time of infection in RV 217.
  2. Willing to begin Genvoya® as soon as entering this study but not later than 7 days from study enrollment.
  3. Successfully passed Test of Understanding (TOU) with a score of 80% or more on ten questions after three attempts.
  4. Adult from 18 to 50 years of age.
  5. Able to participate for 96 weeks of study visits
  6. In general good health as determined by the PI or his/her designee
  7. Willing to have photo or fingerprint taken for identification purposes
  8. No history of ART for any reason, i.e., treatment naïve and no HIV-post-exposure prophylaxis (PEP) or HIV-pre-exposure prophylaxis (PrEP)) within 90 days prior to enrollment
  9. Willing to have blood samples collected and stored.
  10. Adequate renal function: estimated creatine clearance of >50 mL/min according to the Cockroft Gault formula 2 weeks prior to enrollment
  11. Urine clean catch: glucose < trace and protein <1+ or as per site-specification 2 weeks prior to enrollment
  12. Weight is > 35 kg
  13. Female (only women of childbearing potential) Specific Criteria:

Negative pregnancy test 48 hours prior to enrollment:

Commits to continued use of adequate birth control method for 96 weeks of the study and prior to receiving study ART. Adequate birth control is defined as follows: Contraceptive medications delivered orally, intramuscularly, vaginally, or implanted, underneath the skin, surgical methods (hysterectomy or bilateral tubal ligation), condoms, diaphragms, intrauterine device (IUD), or abstinence. If depending on hormonal contraception, check package insert for drug interactions and/or consider adding a second barrier method.

Exclusion Criteria:

  1. Any chronic or clinically significant medical condition that in the opinion of investigator would jeopardize the safety or rights of the volunteer, including but not limited to chronic hepatitis, renal insufficiency or failure; clinically significant forms of drug or alcohol abuse, mental illness, severe asthma, psychiatric disorders, heart disease, or cancer; or a physical finding on examination considered indicative of significant disease such as murmur (other than functional), hepatosplenomegaly, focal neurological deficit, etc.
  2. Untreated AIDS-related opportunistic infection
  3. An AIDS defining condition diagnosed within 30 days
  4. Positive Hepatitis B surface antigen at any time in the past
  5. Requiring use of any medication that is contraindicated with Genvoya®. See Appendix I and the package insert
  6. Women who are breast-feeding

There are no inclusion/exclusion criteria based on CD4 count because CD4 count can be transiently diminished during acute HIV infection and ART initiation during early or acute HIV infection offers the potential benefit of limiting reservoir seeding and preventing immune destruction regardless of peripheral CD4 count at the time of treatment initiation.

Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 50 Years   (Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Uganda
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03877536
Other Study ID Numbers  ICMJE RV 392
WRAIR 2393 ( Other Identifier: WRAIR )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Henry M. Jackson Foundation for the Advancement of Military Medicine
Study Sponsor  ICMJE Henry M. Jackson Foundation for the Advancement of Military Medicine
Collaborators  ICMJE Gilead Sciences
Investigators  ICMJE
Study Chair: Christina Polyak, MD, MPH Henry M. Jackson Foundation in support of MHRP
PRS Account Henry M. Jackson Foundation for the Advancement of Military Medicine
Verification Date April 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP